Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin after catheter ablation for atrial fibrillation with elevated natriuretic peptides
ChiCTR2200063482Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin in Atrial fibrillation (AFib) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: N-terminal pro-B-type natriuretic peptide. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ChiCTR2200063482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063482.